Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib

NCT01752933 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01752933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01752933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
September 30, 2015
Enrollment
52 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma